Effectiveness of New Analgesic Strategy Compared to the Usal Antalgic Strategy (DREPANOX)

New Analgesic Strategy Combining Nitrous Oxide, Nefopam, Acetaminophen and Morphine Compared to the Usal Antalgic Strategy (Acetaminophen and Morphine) for the Treatment of Acute Sickle Cell Disease Pain in the Emergency Room

Quality of life of adult patients with sickle cell disease is deeply impaired by severe adverse medical events that inadvertently occur throughout their time life. Indeed, patients not presenting a life threatening condition often present to the emergency department with sickle cell disease crisis related pain. Currently, the effectiveness of specific analgesic strategies for treating sickle cell disease crisis related pain are mostly based on acetaminophen and opioid derivates combination along with oxygen delivery. Those strategies are effective but may last up to half an hour to obtain pain relief. This delay mostly depends on the availability of venous access and on individual patient response to treatment. Nitrous oxide is a volatile efficient analgesic therapy that has been repeatedly shown to allow rapid analgesia in the emergency department setting.

The investigators hypothesise that a new analgesic strategy (rapid optimized analgesic strategy) including nitrous oxide and nefopam would be as safe and more rapidly effective than current analgesic strategy.

Study Overview

• Status: Completed
• Conditions: Sickle Cell Anemia
• Intervention / Treatment: Drug: current analgesic strategy; Drug: Rapid optimized analgesic strategy

Detailed Description

Purpose of the study:

The main objective is to evaluate the effectiveness of an optimized combination of analgesic therapies for treating uncomplicated sickle cell disease crisis at initial visit to the emergency room of the Henri Mondor hospital.

Secondary objectives:

• Total amount of morphine required during the first 4 hours in the hospital emergency.
• Overall amount of morphine administered on the duration of patient stay in hospital Henri Mondor.
• Side effects of analgesic strategies
• Adverse medical events
• Length of hospital stay.

• 7-day and 1-month follow-up and collection of following data:

  1. Total number of sickle cell disease crises
  2. Number of subsequent readmission and/or visit to an ED
  3. Quality of life (EuroQol EQ-5D, and SF-36)
  4. Patient satisfaction: pain treatment satisfaction scale. Study design: prospective monocentric open-label randomized controlled trial Number of patients: 200 Follow up per patient: 1 month, Study enrolment period: 25 months.

Contraindications to nefopam administration: hypersensitivity to nefopam, benign prostatic hypertrophy and glaucoma, or history of seizures.

• contraindication to morphine administration hypersensitivity to morphine, decompensate respiratory failure, acute head trauma, uncontrolled epilepsy, severe hepatocellular failure, intracranial hypertension, use of buprenorphine or nalbuphine Contraindications to MEOPA administration, intra-cranial hypertension, non cooperative patient (sleepiness; encephalopathy, refusal to participate), pneumothorax, emphysema, pneumoperitoneum, digestive occlusion, pneumomediastinum, air embolism, diving accident , facial trauma, patients who recent administration of an ophthalmic gas (SF6, C3F8, C2F6) < 3 months).
• contraindication to the use of oxygen: no-absolute contraindication no health insurance, adults under tutelage

Main criterion:

Proportion of patients relieved (pain intensity by simple numerical scale <4) to 30 minutes of their arrival in the emergency department.

Secondary criteria:

• amount of morphine administrated within the first 4 hours of presentation to the emergency department
• overall amount of morphine administrated during hospital stay
• adverse event related with study treatment
• adverse medical events during hospitalization
• length of stay.

• 7-day and 1-month follow-up to collect the following data:

  1. Total number of sickle cell disease crises
  2. Number of subsequent readmission and/or visit to an ED
  3. Quality of life (EuroQol EQ-5D, and SF-36)
  4. Patient satisfaction: pain treatment satisfaction scale.

• Study Type: Interventional
• Enrollment (Actual): 176
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Créteil, France, 94000
    • Henri Mondor Hospital, Emergency Department

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• male adult patient with sickle cell anemia,
• age ≥ 18 years,
• main complaint : sickle cell crisis pain,
• initial numeric pain intensity scale at presentation > 4,
• admission to the ED during working hours (amendment n°2-15/02/2010:from 8h to 20h), from Monday to Friday

Exclusion Criteria:

• female adult patient
• complicated sickle cell crisis or admission requirement to an ICU
• recent hospitalisation (< 10 days) for the same complaint
• previous inclusion in the study
• contraindication to anyone of the study drugs
• no medical insurance
• incompetent adult

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: 2; Combination of acetaminophen, morphine	Drug: current analgesic strategy; paracetamol 1 g per os nasal oxygen therapy 1 amp of morphine 10 mg / 10 cc of glucose 5 %, by repeated bolus administration
Experimental: 1; Combination of acetaminophen, nitrous oxide, nefopam, morphine	Drug: Rapid optimized analgesic strategy; Oral treatment : 1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar Nitrous oxide inhalation with initial output of 9 L/min subsequently Intravenous morphine bolus of 3 mg Nitrous oxide interruption after 5 minutes of the initial morphine bolus

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Rate of pain relief (Numeric Pain Intensity Scale < 4)	at 30 min after admission to the ED

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall amount of morphine delivered		during the first 4 hours of ED presentation
Overall amount of morphine delivered		during the hospital stay following ED presentation and enrolment in the study
Analgesic drugs related adverse events		during the hospital stay following ED presentation and enrolment in the study
Length of hospital stay		during the hospital stay
Overall number of sickle cell crisis and patients'quality of life (EuroQol-EQ 5D, SF-36) and patients' satisfaction regarding pain management (pain management satisfaction questionnaire)		at 7 days and 30 days of follow-up.
measurement of oxygen saturation in tissue (amendment n°1 - 14/09/2009)	measurement of oxygen saturation in tissue	in 4hours after admission to the emergency

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Investigators: Principal Investigator: Aline SANTIN, MD, Assistance Publique - Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start: October 1, 2009
• Primary Completion (Actual): October 1, 2012
• Study Completion (Actual): November 1, 2012

Study Registration Dates

• First Submitted: April 1, 2009
• First Submitted That Met QC Criteria: April 1, 2009
• First Posted (Estimate): April 2, 2009

Study Record Updates

• Last Update Posted (Estimate): December 18, 2012
• Last Update Submitted That Met QC Criteria: December 17, 2012
• Last Verified: November 1, 2012

More Information

Terms related to this study

• Keywords: Pain; Quality of life; Anemia; Analgesic; Sickle Cell; Emergency treatment
• Additional Relevant MeSH Terms: Hematologic Diseases; Genetic Diseases, Inborn; Anemia; Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Hemoglobinopathies; Anemia, Sickle Cell; Physiological Effects of Drugs; Peripheral Nervous System Agents; Sensory System Agents; Analgesics
• Other Study ID Numbers: P070605-OST07010